Published in Cancer Weekly, June 24th, 2003
Findings reported in the June 15, 2003 issue of Cancer indicate that more than 33% of women with metastatic breast cancer who overexpress the HER2 receptor and are treated with trastuzumab, develop symptomatic CNS metastases, often times in spite of decreased or stable metastatic disease elsewhere in the body.
The authors suggested that because of the devastating impact of neurological impairment and the high incidence of brain metastases while on trastuzumab, "it may be worthwhile to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.